36122
document
The effect of cyclosporin administered during a third-party blood transfusion protocol on humoral immune responses . Antigen pre-treatment in animals undoubtedly prolongs graft survival . In man , however , routine pre-transplantation blood transfusions have recently become controversial , principally because of the adverse effect of transfusion-induced sensitisation on graft survival rates . We have monitored the effect of cyclosporin administered during a planned programme of third-party blood transfusions on the development of both cytotoxic and anti-idiotypic antibodies . A total of 24 patients were recruited to the study ; ten received cyclosporin with blood transfusions ( BT ) ( group 1 ) , 14 received BT alone ( group 2 ) . Anti-HLA antibodies developed in 3 of 9 patients in group 1 and 8 of 12 patients in group 2 ( P less than 0.05 ) . Anti-idiotypic antibody activity was detectable in 9 of 9 patients in group 1 and 7 of 12 patients in group 2 ( P less than 0.006 ) . The mechanism by which cyclosporin can prevent an anti-HLA antibody response and promote an anti-idiotypic response is unclear .
36123
Intervention_Pharmacological
cyclosporin
36124
Intervention_Physical
Antigen pre-treatment
36125
Intervention_Pharmacological
cyclosporin
36126
Intervention_Pharmacological
cyclosporin with blood transfusions ( BT )
36127
Intervention_Pharmacological
BT alone
36128
Outcome_Physical
graft survival
36129
Outcome_Physical
graft survival rates
36130
Outcome_Physical
both cytotoxic and anti-idiotypic antibodies
36131
Outcome_Physical
Anti-HLA antibodies
36132
Outcome_Physical
Anti-idiotypic antibody activity
36133
Outcome_Physical
anti-HLA antibody response
36134
Outcome_Physical
anti-idiotypic response
36135
Participant_Condition
third-party blood transfusion protocol
36136
Participant_Condition
Antigen pre-treatment in animals